Osong Medical Innovation Foundation, Korea University Research and Business Foundation

Ajou University Industry-academic Cooperation Foundation

Lg Electronics Inc.

Coway Co., Ltd

Mjcell Bio Co., Ltd.

Kyung-Mi Lee

Seon Ah Lim

Yong Sung Kim

Ye Jin Kim

Jun-Hyoung Bae

Young-kwan Lee

Cassian Yee

Jeongwon Sohn

Jang-Mi Lim

Chan-Yong Lee

Seung-Hyun Jeon

Baeckseung Lee

Yoon Lee

The present invention relates to an expansion culture method for natural killer cells and, more particularly, to an expansion culture method for natural killer cells, wherein the cultured natural killer cells are treated with an HDAC inhibitor. According to the present invention, when natural killer cells are subjected to in vitro expansion culture, the cells can be restrained from undergoing cell death, resulting in a remarkable improvement in the viability and production yield of the cells. Thus, natural killer cells, which are needed for cell therapy, such as cancer therapy, etc., can be obtained effectively.

Expansion culture method for human-derived natural killer cells by using HDAC inhibitor

The present invention relates to a chimeric antigen receptor having a ligand specifically targeting an anthrax toxin receptor (ANTXR), and, more specifically, to: a nucleic acid encoding a chimeric antigen receptor comprising ligand PA63 specifically binding to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2); a vector comprising the nucleic acid encoding a chimeric antigen receptor; and a recombinant cell comprising the vector; a pharmaceutical composition for preventing or treating solid cancer, comprising the recombinant cell; and a treatment method. Solid cancer can be treated using an anti-ANTXR chimeric antigen receptor (CAR)-T cell, according to the present invention, and since the chimeric antigen receptor (CAR)-T cell is administered to patients with solid cancer for whom anti-cancer drug administration is not effective, especially patients with pancreatic cancer, drug administration is limited, and customized solid cancer prevention or treatment, which are efficient and safe, is possible.

Human anti-ANTXR chimeric antigen receptor and use thereof

A heterodimeric Fc-fused protein and a pharmaceutical composition comprising the heterodimeric Fc-fused protein are disclosed. The heterodimeric Fc-fused protein includes first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to at least one of the N-terminus or the C-terminus of the first Fc region and/or the second Fc region, wherein CH3 domains of the first Fc region and the second Fc region are mutated such that the formation of a heterodimer is promoted. When the heterodimeric Fc-fused protein is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.

IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same

Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and/or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity.

Method of expanding NK cell and composition for culturing

A heterodimeric Fc-fused protein and a pharmaceutical composition comprising the heterodimeric Fc-fused protein are disclosed. The heterodimeric Fc-fused protein comprises first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to at least one of the N-terminus or the C-terminus of the first Fc region and/or the second Fc region, wherein CH3 domains of the first Fc region and the second Fc region are mutated such that the formation of a heterodimer is promoted. When the heterodimeric Fc-fused protein according to the present invention is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.

There is provided a water leakage preventing humidification apparatus including: a housing; a water tank installed in the housing and storing water for humidification; a water bottle having a water guide unit having an outlet formed therein to allow water to flow out therefrom, and installed in the water tank to provide water for humidification to the water tank; an installation part disposed in the water tank and having a confinement water formed to surround at least a portion of the circumference of the water guide unit of the water bottle and a water tank input hole formed on one end of the bottom surface along which water flowing out through the outlet flows and communicating with the water tank; and a humidification unit provided to perform humidification with water stored in the water tank.

Water leakage preventing humidification apparatus

Video camera

Growing community of inventors

Seoul, South Korea

Kyung-Mi Lee